HOST RESPONSE TO INFECTION

Antibodies to streptococcal inhibitor of complement function and M peptides in a post-streptococcal glomerulonephritis endemic region of Australia.

K. S. SRIPRAKASH*†‡, JON HARTAS* and ANDREW WHITE*§

*Menzies School of Health Research, Darwin; †Co-operative Research Centre for Aboriginal and Tropical Health, Darwin; ‡Queensland Institute of Medical Research, Brisbane and §Remote Health Service, Alice Springs

Post-streptococcal glomerulonephritis (PSGN) is an immune-mediated disease in which an immune complex containing a streptococcal antigen are deposited in affected glomeruli. Strains of only some M types are known to be associated with PSGN. A secretory protein called SIC inhibits complement function. Whereas all M1 and M57 strains express closely related SIC (CRS), all M12 and M55 strains express distantly related SIC (DRS) proteins. Strains belonging to these four M types are historically associated with PSGN. This study used ELISA to analyse 112 sera from individuals with a recorded history of PSGN and 86 sera from individuals who had no such recorded history, all from a PSGN endemic region in tropical Australia. Antibody reactions to CRS, DRS and peptides corresponding to the N-termini of M1, M5, M12, M49, M55 and M57 antigens were assessed. A large proportion of the population showed reactions to each of these antigens and there was no correlation between CRS seropositivity and antibodies to CRS-positive M types. Likewise there was no correlation between DRS seropositivity and antibodies to DRS-positive M types. Interestingly, in this community endemic for PSGN a significantly higher proportion of DRS seropositive subjects had a recorded history of PSGN than did DRS seronegative subjects. DRS may have a predictive value for PSGN diagnosis or a role in PSGN pathogenesis.

Introduction

Streptococcus pyogenes (Lancefield group A streptococcus, GAS) is an aetiological agent for pharyngitis and pyoderma. An important sequela of GAS infection is post-streptococcal glomerulonephritis (PSGN) [1], which has been shown to be associated with long-term renal dysfunction [2]. M protein is a major GAS surface antigen, which elicits a protective immune response, that is persistent for some M proteins [3]. Only certain M serotypes have been shown to be associated with PSGN [1, 4, 5].

Sero type 1 strains of S. pyogenes express a secretory protein, that inhibits complement-mediated cell lysis [6]. The gene for this streptococcal inhibitor of complement function (SIC) has been found only among M types 1 and 57 of 55 M types tested. SIC from strain AP1, an M1 strain, has been shown to bind to clusterin and to be incorporated into the complement membrane attack complex (MAC). Subsequently, two classes of SIC were described – those closely related to the SIC from AP1 (CRS) and those distantly related to the SIC from AP1 (DRS) [7]. Both CRS and DRS have a similar leader sequence and show 85% similarity in a stretch of 55 residues in the C-proximal half of the 25–35-kDa protein; otherwise, CRS and DRS share little sequence similarity.

All strains containing emm1 (gene for M1 protein) and emm57 possess CRS genes (crs1 and crs57, respectively), whereas emm12 and emm55 strains have DRS genes (drs12 and drr55, respectively). Moreover, in emm1, emm12 and emm55 strains, the crs1, drr12 and drr55 are located immediately downstream from their respective emm locus and form a part of the mga regulon [8]. In emm57 strains, crs57 is outside the mga
PSGN is an immune-mediated disease [9, 10]. Immune complexes containing a streptococcal antigen are deposited in the glomeruli of PSGN patients. Only S. pyogenes M types historically associated with PSGN express such an antigen. The following were reported to have a role in the pathogenesis of PSGN [10–15]: (i) one or more streptococcal extracellular products including M protein, (ii) a nephritis strain-associated protein, (iii) a pre-absorbing antigen, (iv) a nephritis-associated plasmin receptor (NAPr) and (v) a zymogen encoded by SpeB gene. Parra et al [14] compared the antibody response to streptococcal cysteine protease zymogen, streptolysin O and DNAase B in populations from three South American countries. Although they found that anti-zymogen titres were consistently higher in the PSGN patients than in healthy controls, there was no significant difference between PSGN patients and a control group with uncomplicated impetigo. Similarly, antibodies to NAPr were found in a significantly greater proportion of PSGN patients than in control groups [13]. Age-related acquisition of NAPr antibodies was noted, possibly resulting from repeated streptococcal infections. These antibodies appear to be long lasting.

Rodríguez-Iturbe [16] described three criteria for potential nephritogenic antigens. They are that the antigen (i) is secreted only by nephritis-associated GAS strains, (ii) is present in glomeruli of PSGN patients, and (iii) induces antibodies in convalescent sera from PSGN patients. SIC fulfils these criteria as it is a secretory product restricted to M types that are historically associated with PSGN, it is highly immunogenic [17], and through its interaction with MAC and clusterin [6] SIC has a potential to be located in affected glomeruli. To test the hypothesis that SIC or its variants play a role in the pathogenesis of PSGN, this study investigated relationships between antibodies against CRS/DRS, antibodies against the CRS/DRS-associated plasmin receptor (NAPr) and (v) a zymogen encoded by SpeB gene. Parra et al [14] compared the antibody response to streptococcal cysteine protease zymogen, streptolysin O and DNAase B in populations from three South American countries. Although they found that anti-zymogen titres were consistently higher in the PSGN patients than in healthy controls, there was no significant difference between PSGN patients and a control group with uncomplicated impetigo. Similarly, antibodies to NAPr were found in a significantly greater proportion of PSGN patients than in control groups [13]. Age-related acquisition of NAPr antibodies was noted, possibly resulting from repeated streptococcal infections. These antibodies appear to be long lasting.

Materials and methods

**Strain and peptides**

*S. pyogenes* M type 1 strain 2031 was obtained from the Group A Streptococcus Reference Laboratory in Prague, Czech Republic. NS488 is a Northern Territory strain and peptides were biotinylated at the C-terminus. The crs1 gene from strain 2031 was amplified with SIC-specific forward and reverse primers (CRSf: GGGGGATCCATGAATATTAGAATAATGAGTGAA ATAG and CRSr: AAACATGATCTCGGATATCCCTT TACGTTGCTG, respectively) in a PCR. The amplified product was cloned into pQE30 (Qiagen) upstream of the His6 tag. Likewise, drs12 was amplified from NS488 with CRSf and DRSr (GGGCTGCAGGCCAA GAATCTTTCTATTTAATACC) as primers. The recombinant CRS and DRS (rCRS and rDRS) were purified from cell lysates of Escherichia coli harbouring appropriate clones with Ni-NTA affinity columns (Qiagen) according to the manufacturer’s instructions, with a buffer containing 8 M urea. The eluates from the columns were extensively dialysed against phosphate-buffered saline (PBS). The purified proteins migrated between 30 and 45 kDa as characterised by SDS-PAGE followed by immunoblotting with antibodies raised against rCRS and rDRS in rabbits.

**Study population**

Sera were collected from an Australian Aboriginal island community in Northern Australia. Population-based health screening was conducted on the island between 1992 and 1999 and a large proportion of the community participated. Part of the study included review of medical records for history of PSGN and collection of serum. In all, 112 participants had a history of PSGN and their sera were tested along with those from 86 control subjects who had no known history of PSGN. The Joint Institutional Ethics Committee of the Royal Darwin Hospital and the Menzies School of Health Research approved the study, as did the local community health board. Consent was obtained from each individual or guardian at the time of the screening.

**ELISA**

Detection of CRS and DRS antibodies in the sera. Flat-bottomed immunoplates (Nunc) were coated by adding 100 μl of rCRS or rDRS 100 μg/ml in carbonate buffer (pH 9.6) per well and incubating overnight at 4°C. After blocking with denatured casein hydrolysate 5% in PBS, the bound proteins were allowed to react with a 1 in 300 dilution of human serum in the same buffer containing Tween 20 0.05% for 1 h at room temperature (RT). After washing with Tween 20 0.05%
in PBS and treating with a secondary anti-human IgG antibody conjugated to alkaline phosphatase (Sigma), the reactions were detected with 4-nitrophenyl-disodium orthophosphate. The optical density (OD) was measured at 405 nm after incubation for 1 h at room temperature. Sera from four non-Aboriginal laboratory workers who had no recorded history of PSGN showed no reaction to the rCRS or rDRS proteins by these criteria.

Detection of antibodies to peptides corresponding to M1, M5, M12, M49, M55 and M57. Flat-bottomed immunoplates (Nunc) were coated with streptavidin (50 µg/ml) overnight. After blocking as above, biotinylated peptides were added to the wells (50 µl, 0.66 µg/ml). The plates were incubated at room temperature for 1 h. After washing with Tween 20 0.05% in PBS, sera (1 in 300 dilution) were added and incubated for 1 h at RT. The reactions were measured as described above. Sera from four non-Aboriginal laboratory workers were also tested; past infection with one or more GAS strains belonging to these M types over the past 10 years; for example, strains with emm12 or emm49 sequence were rarely isolated, whereas emm55 types were common. However, the prevalence of specific strains at the time when most participants in this study were children is not known.

Results and discussion

In a cross-sectional study of an island community of approximately 1400 residents, sera from 198 subjects were analysed, representing c. 15% of the population. Both sexes were equally represented (male/female = 106/92) and the majority (78%) of sera were from individuals older than 15 years (age range 10–58 years).

In conjunction with testing for seroreaction to CRS and DRS, four M peptides representing the four CRS- and DRS-positive M types, and two M peptides representing two CRS- and DRS-negative M types (M5 and M49) were also tested. Table 2 presents a summary of the distribution of data for the eight antigens tested. The distribution is skewed towards low values. Fig. 1 shows the proportions of sera reactive to CRS, DRS and the M peptides tested.

In all, 113 sera (57%) reacted with CRS and 109 (55%) reacted with DRS; 73% of the sera reacted with either CRS or DRS and 77 sera (39%) reacted with both the antigens. The results presented here show that like CRS, DRS proteins are immunogenic in natural infection and >70% of the sera from this population have antibodies to either of these antigens. A total of 179 sera (90%) reacted with at least one of the six M peptides, 20 (10%) reacted with only one, 80% reacted with two or more and almost 37% reacted with all six peptides. These results suggest that most of the study population has been exposed to multiple serotypes. These results are not unexpected given the very high frequency of skin sepsis in the population [18, 20] and the high antigenic diversity of circulating GAS strains in this geographical location [21, 22].

Rates of seropositivity to the peptides that represent CRS- or DRS-positive M types, or CRS- and DRS-negative M types were similar (Fig. 1). Serology in this study does not reflect the rate of isolation of strains belonging to these M types over the past 10 years; for example, strains with emm12 or emm49 sequence were rarely isolated, whereas emm55 types were common. However, the prevalence of specific strains at the time when most participants in this study were children is not known.

There was a positive correlation between the presence of antibodies to CRS and antibodies to DRS (p < 0.001); 68% of sera showing antibodies to CRS also

### Table 2. Summary of distributions of the raw scores of OD in ELISAs

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Mean</th>
<th>Range</th>
<th>25th percentile</th>
<th>Median</th>
<th>Cut off</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1</td>
<td>0.11</td>
<td>0.0–0.98</td>
<td>0.04</td>
<td>0.09</td>
<td>0.05</td>
</tr>
<tr>
<td>M57</td>
<td>0.12</td>
<td>0.0–1.00</td>
<td>0.05</td>
<td>0.09</td>
<td>0.08</td>
</tr>
<tr>
<td>M5</td>
<td>0.11</td>
<td>0.0–0.95</td>
<td>0.04</td>
<td>0.09</td>
<td>0.05</td>
</tr>
<tr>
<td>M49</td>
<td>0.11</td>
<td>0.0–0.86</td>
<td>0.04</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>CRS</td>
<td>0.18</td>
<td>0.2–0.66</td>
<td>0.06</td>
<td>0.11</td>
<td>0.06</td>
</tr>
<tr>
<td>DRS</td>
<td>0.12</td>
<td>0.1–1.37</td>
<td>0.03</td>
<td>0.06</td>
<td>0.10</td>
</tr>
</tbody>
</table>

*The cut-off point used seropositivity was three times the mean of the lowest quartile.*
reacted with DRS, whereas only 38% of CRS antibody-negative sera reacted with DRS. It is unlikely that sequence variation in CRS [23] would influence the above outcome, as several linear B-cell epitopes spanning the entire length of CRS are immunogenic in natural infection [17] and it is unlikely that the variants exhibit changes in all the epitopes. Taken together, these results suggest that a proportion of the population had been infected previously with both CRS- and DRS-positive M types. This should then reflect in a high prevalence of antibodies to M12 and M55 peptides among the sera containing antibodies to M1 and M57 peptides. As expected, 142 (93%) of the sera that reacted with the M1 or M57 peptide also reacted with the M12 or M55 peptide; a similar proportion of the DRS-negative sera (79%) reacted with these M peptides (p = 0.608). Two factors may have obscured the relationships between seropositivity to CRS/DRS and seropositivity to the M peptide. First, like M1 antibodies [17], M57, M12 and M55 antibodies may preferentially decline over time relative to CRS/DRS antibodies. Second, because M proteins are surface-bound, early treatment with antibiotics may remove the antigen along with the pathogen and suppress the type-specific antibody response [24], whereas CRS and DRS are secretory products, which may continue to circulate even after the disappearance of infecting GAS.

Fig. 1. Proportion of sera that reacted with CRS, DRS and the six M peptides; 198 sera were analysed by ELISA for antibodies to the streptococcal antigens. 1, CRS; 2, DRS; 3, CRS or DRS; 4, CRS + DRS; 5–10, M1, M57, M12, M55, M5 and M49 peptides, respectively; 11, at least one M peptide; 12, only one M peptide; 13, two or more M peptides; 14, all six M peptides. Three times the mean OD405 of the lowest quartile was used for the cut-off value in these ELISAs (see text). The range of these cut-off values for the eight individual antigens tested in this study was 0.04–0.1. The sequences of peptides are shown in Table 1. Purified recombinant proteins were used for CRS and DRS.

As CRS appears to be restricted to only M1 and M57 serotypes, and DRS appears to be restricted to M12 and M55 types, the observed congruence between the above positive associations (M1/M57 and M12/M55 seroreactions, and CRS and DRS seroreactions) was not surprising. It was also anticipated that CRS seropositivity would be directly associated with seropositivity to M1 and M57 peptide and that DRS seropositivity would be associated with seropositivity to M12 and M55 peptide. However, such associations were not found. Of the 113 CRS-positive sera, 81% reacted with M1 or M57 peptides compared with 60 (71%) of CRS-negative sera (p = 0.09). Of the 109 DRS-positive sera, 76% reacted with M12 or M55 peptide; a similar proportion of the DRS-negative sera (79%) reacted with these M peptides (p = 0.608). Two factors may have obscured the relationships between seropositivity to CRS/DRS and seropositivity to the M peptide. First, like M1 antibodies [17], M57, M12 and M55 antibodies may preferentially decline over time relative to CRS/DRS antibodies. Second, because M proteins are surface-bound, early treatment with antibiotics may remove the antigen along with the pathogen and suppress the type-specific antibody response [24], whereas CRS and DRS are secretory products, which may continue to circulate even after the disappearance of infecting GAS.

The association between history of PSGN and seropositivity to CRS, DRS and the M peptides was examined. The proportion of individuals with past history of PSGN was the same (56%) for those with and those without antibodies to CRS. However, there was a significant association between DRS seropositivity and history of PSGN (Fig. 2); 71 (65%) of 109 DRS seropositive subjects had a recorded history of PSGN as opposed to 46% among the DRS seronegative subjects (p = 0.009). There was no correlation between antibodies to any of the M peptides tested and history of PSGN. Given that PSGN is highly endemic in this population, and the disease has been reported to occur in a subclinical to clinical disease ratio of 4 to 1 [25]; many individuals may have had PSGN without having the diagnosis made. Therefore, the associations of

Fig. 1. Proportion of sera that reacted with CRS, DRS and the six M peptides; 198 sera were analysed by ELISA for antibodies to the streptococcal antigens. 1, CRS; 2, DRS; 3, CRS or DRS; 4, CRS + DRS; 5–10, M1, M57, M12, M55, M5 and M49 peptides, respectively; 11, at least one M peptide; 12, only one M peptide; 13, two or more M peptides; 14, all six M peptides. Three times the mean OD405 of the lowest quartile was used for the cut-off value in these ELISAs (see text). The range of these cut-off values for the eight individual antigens tested in this study was 0.04–0.1. The sequences of peptides are shown in Table 1. Purified recombinant proteins were used for CRS and DRS.
This work was supported by the Australian National Health and Medical Research Council, the Australian Kidney Foundation and the National Heart Foundation of Australia. We acknowledge the support and participation of the Tiwi Community, Tiwi project workers and the staff in the Health Clinic at Nguyu. We also thank Dr Wendy Hoy and Ms Bev Hayhurst, who initiated and co-ordinated the screening programme, and Drs Trenholm and Gardiner for reading the manuscript.

**Fig. 2.** Proportion of the population with a history of PSGN as determined by the presence or absence of antibodies to CRS and DRS. The data represent sera from 112 subjects with recorded PSGN history and 86 subjects who had no recorded history of PSGN; +ve and –ve represent sera with and without reactions to the antigens, CRS or DRS. *, Statistically significant (p = 0.009).

**Table 2.** Percent with history of PSGN

<table>
<thead>
<tr>
<th>Antibody presence</th>
<th>50%</th>
<th>60%</th>
<th>70%</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRS</td>
<td>5%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>DRS</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

**References**


DRS antibodies may correlate with PSGN.

---


